Last updated 13 days ago

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

144 patients around the world
Available in Chile, Argentina, United States
Alnylam Pharmaceuticals
144Patients around the world

This study is for people with

Obesity
Diabetes
Diabetes mellitus type 2

Requirements for the patient

To 75 Years
All Gender

Medical requirements

Has a body mass index (BMI) of ≥27 kg/m² and <40 kg/m².
Is an adult patient with a confirmed diagnosis of T2DM.
Has a hemoglobin A1c (HbA1c) ≥7% to <10.5%.
Has a BMI of ≥25 kg/m² and <45 kg/m².
Is on a stable dose of either metformin or metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i).
Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection.
Receiving therapies for chronic weight management or antidiabetic medications other than metformin and SGLT2i.
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy